NCT04688853 - A Study to Investigate the Safety and Efficacy of TEG002 in Relapsed/Refractory Multiple Myeloma Patients | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 13, 2021

Primary Completion Date

July 30, 2023

Study Completion Date

July 30, 2024

Conditions

Multiple Myeloma, RefractoryMultiple Myeloma in RelapseMultiple Myeloma

Interventions

BIOLOGICAL

TEG002

TEG002 cells are autologous T cells transduced with a specific γδTCR

Trial Locations (3)

Massachusetts General Hospital, Boston

Beth Israel Deaconess Medical Center, Boston

Dana Farber Cancer Institute, Boston